Compare Novo Nordisk A/S (NVO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $46.32 (market cap $207.85B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SGOV | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $100.74 |
52-Week Low | $35.29 | $100.28 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% with a bearish technical signal from moving averages. It offers a defensive cash alternative, highlighted by recent institutional stake changes and a focus on ultra-short Treasury exposure amid market volatility. The ETF provides monthly distributions, with recent dividends around $0.30 per share.
The outlook remains stable as a low-risk income vehicle, benefiting from rising yields and investor defensive pivots. Key risks include interest rate fluctuations and macroeconomic shifts, but its principal protection and liquidity appeal to cautious investors seeking yield above traditional savings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
